Introducing Tailored Covalency

Traditional oral small molecule drugs are convenient, but often have side effects because they may not be selective.

Injectable antibody drugs are highly specific therapies, but an injection is not convenient for the patient.

What if you could have the best of both worlds?

Principia’s novel approach to drug development combines the dosing convenience of a small molecule drug with characteristics of an antibody. Our drugs are designed to be effective, potent, selective, durable and safer than traditional small molecule drugs.

Learn More

A pipeline of differentiated drug candidates that may offer superior safety and efficacy

Autoimmune / Inflammatory Diseases

Research
Preclinical
Phase 1
PRN1008: BTK Inhibitor / Rheumatoid Arthritis
   
PRN1008: BTK Inhibitor / Undisclosed Orphan Indication
   
IL-17 Pathway Inhibitor: Autoimmune / Inflammatory
   
Undisclosed: Autoimmune / Inflammatory
   

Oncology

PRN1371: FGFR Inhibitor / Multiple Cancers
   
BTK Inhibitor: Hematologic Malignancies